




EMLc

ATC codes: **B01AA03**

Indication	Atrial fibrillation <span style="background-color: #00a651; color: white; padding: 2px;">ICD11 code: BC81.3Z</span>
INN	Warfarin
Medicine type	Chemical agent
List type	Core (EML) Complementary (EMLc)
Formulations	Oral > Solid: 5 mg (sodium salt) ; 1 mg (sodium salt) ; 2 mg (sodium salt) ; 0.5 mg (sodium salt) (EMLc)
EML status history	First added in 1977 ( <a href="#">TRS 615</a> ) Changed in 1979 ( <a href="#">TRS 641</a> ) Changed in 1982 ( <a href="#">TRS 685</a> ) Changed in 1987 ( <a href="#">TRS 770</a> ) Changed in 2007 ( <a href="#">TRS 950</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	Medicines within the same pharmacological class can be used
Therapeutic alternatives limitations	Therapeutic alternatives to be reviewed (2023)
Therapeutic alternatives limitations for EMLc	Therapeutic alternatives to be reviewed (2023)
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Warfarin</a> 
DrugBank	<a href="#">Warfarin</a> 

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the therapeutic alternatives for warfarin be reviewed.

